AbbVie

$ABBV AbbVie Has It All: Growth, Dividend Growth and Compelling Valuation (NYS:ABBV)

2019-06-25

Research Articles

Introduction I have held AbbVie (ABBV) since it was originally spun off from Abbott Labs.  Moreover, I have been aggressively adding to my position for clients needing current income and dividend growth.  All in all, it has been an excellent performer in spite of the fact that it is being ridiculously undervalued by Mr. Market.  […]

Disclaimers: F.A.S.T. Graphs, Inc. is not a broker-dealer or a registered investment adviser. Under no circumstances does any information on Fastgraphs.com constitute a recommendation to buy or sell a security, nor does it give investment advice. This is to include any publications or articles on Fastgraphs.com. Fastgraphs.com is a research tool to be used by its subscribers in conjunction with the subscribers’ additional research and due diligence. The information on this site is in no way guaranteed for completeness or accuracy.